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Tobacco smoking and excessive alcohol consumption are known to have detrimental effects 
on multiple body organs including the cardiorespiratory system and gastrointestinal (GI) tract. 
The World Health Organisation estimate that 1.1 billion people smoke worldwide, and 
although this number is declining overall, prevalence continues to rise in certain regions, 
particularly in low and middle-income settings. Global prevalence of heavy episodic 
consumption of alcohol is also a major public health issue. An estimated 7.5% of adults are 
heavy drinkers, but this is considerably higher (up to 17%) in some developed regions, such as 
Europe and North America. Public knowledge, and awareness amongst clinicians, of smoking 
and irresponsible alcohol consumption as ‘bad’ behaviours is generally well understood. 
However, there are some nuances, and research gaps, in the relationships between alcohol, 
smoking and the GI tract, that are described in detail in this issue.  
 
Both tobacco smoke and alcohol are established carcinogens. Over 14 million new cancer 
diagnoses are made globally each year and four of the ten most common cancers develop 
within the GI tract. These include colorectal, gastric, liver and oesophageal cancer. The 
development of GI malignancies are multi-factorial, attributable to a combination of 
environmental and genetic factors. Overall, GI cancer incidence is increasing, but this has 
been met with advances in earlier detection of cancers, the development of new surgical 
techniques and improved chemotherapy agents to improve overall patient survival. However, 
further progress is required – for example, the success seen in improving colorectal cancer 
outcomes (in which the five-year survival is approximately 65%) has not been replicated in 
oesophageal or pancreatic cancer, which have poor five-year survival rates of less than 20%.  
Even though smoking and alcohol have been identified in epidemiological studies as 
modifiable risk factors involved in the aetiology of many (but not all) GI malignancies, 
understanding the role of these in an individual patient’s disease course and prognosis is 
often unclear.  Indeed, smoking and alcohol consumption can be an uncomfortable subject 
that may not be broached by many clinicians in discussions with these patients, for various 
(often appropriate) reasons. Although some progress has been made, there remains a need to 
better translate our knowledge of lifestyle factors including alcohol and smoking in GI cancer 
risk and prognosis, to educate the public and patients on these roles, and ultimately reduce 
cancer burden.  If it were a medication that had beneficial effects (akin to smoking cessation 
or alcohol intake reduction), would we think twice about prescribing it?  
 
The opportunity of a ‘teachable moment’ is a valuable one, and perhaps it is considered more 
feasible to discuss and address smoking and alcohol behaviours with individuals with pre-
malignant, functional or benign GI diseases than cancer patients. Benign conditions of the GI 
tract, such as pancreatitis and inflammatory bowel disease (IBD), account for significant 
morbidity and mortality within the GI patient population. Furthermore, whilst the general 
trend of GI malignancy is to increase in incidence as individuals get older, benign conditions 
have a greater affinity for younger patients. This can mean a longer duration of disease and a 
significant impact on overall patient quality of life in patients with non-malignant, compared 
with malignant, GI conditions.  IBD is one such example of a benign condition that can 
impact significantly on patient’s quality of life. This can be through multiple hospital 
admissions for disease flare-up, surgical intervention for failed medical treatment and 
progression to malignant disease. As outlined in this issue, discussing smoking already plays 
a major role in IBD patient management.   
 
This issue of Best Practice and Research: Clinical Gastroenterology is dedicated to up-to-
date reviews on the impact of smoking and alcohol on both malignant and benign conditions 
of the GI tract. The most common conditions are discussed in each chapter and summaries of 
evidence provided on the role of smoking and alcohol intake as a risk factors for these 
conditions, impacts of disease course and progression, symptom exacerbation, or patient 
management is provided. Underlying biological mechanisms and novel insights into alcohol, 
smoking and the gut microbiome are also provided. To complete this issue, there is a chapter 
dedicated to practical methods of communicating smoking and alcohol advice to patients. At 
the end of each chapter, key findings are highlighted along with gaps in the current research, 
and what could be done to address these.  
 
We hope that this issue will improve the practice of evidence-based medicine with regards to 
lifestyle advice on alcohol and smoking for GI patients, alert researchers to gaps in our 
understanding, and consequently contribute towards improved quality of care offered to 
patients. 
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